Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Summary: Background In models of irritable bowel syndrome (IBS), asimadoline, a kappa‐opioid agonist, improves pain and abnormal bowel function. Aim To evaluate the effects of three doses of asimadoline and placebo in subjects with IBS through a double‐blind, randomized, placebo‐controlled trial. Methods Patients were randomly assigned to receive asimadoline 0.15, 0.5, 1.0 mg or placebo BID for 12 weeks. The primary efficacy measure was number of months of adequate relief of IBS pain or discomfort, with a prospective plan to evaluate adequate relief data by entry baseline pain and subtype. Several other endpoints were also evaluated. Results Five hundred and ninety‐six patients were randomized. In the ITT population, statistically significant improvement on the primary endpoint was not seen. However, in diarrhoea‐predominant IBS patients with at least baseline moderate pain, asimadoline (0.5 mg) produced significant improvement on total number of months with adequate relief of IBS pain or discomfort (46.7% vs. 20.0%), adequate relief of IBS symptoms (46.7% vs. 23.0%), pain scores (week 12: −1.6 vs. −0.7), pain free days (42.9% vs. 18.0%), urgency and stool frequency (−2.3 vs. −0.3). In patients with alternating IBS, significant improvement was seen on adequate relief endpoints. Asimadoline was well tolerated. Conclusion Asimadoline warrants further evaluation as a treatment for IBS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Agresti, A. (2002) · Wiley Series in Probability and Statistics · doi:10.1002/0471249688 · Cited by 6,746
AGA technical review on irritable bowel syndrome.
Drossman, D. A., Camilleri, M., Mayer, E. A., & Whitehead, W. E. (2002) · Gastroenterology · doi:10.1053/gast.2002.37095 · Cited by 1,384
The Irritable Bowel Syndrome: Review and a Graduated Multicomponent Treatment Approach
Drossman, D. A., & Thompson, W. G. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-12-1009 · Cited by 309
Cited by
Guideline for opioid therapy and chronic noncancer pain
Busse, J. W., Craigie, S., Juurlink, D. N., Buckley, D. N., Wang, L., Couban, R. J., Agoritsas, T., Akl, E. A., Carrasco-Labra, A., Cooper, L., et al. (2017) · Canadian Medical Association Journal · doi:10.1503/cmaj.170363 · Cited by 707
Pain and inflammatory bowel disease.
Bielefeldt, K., Davis, B., & Binion, D. G. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20848 · Cited by 304
Peripheral mechanisms of opioid analgesia
Stein, C., & Lang, L. J. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.12.009 · Cited by 306
Peripheral mechanisms of pain and analgesia
Stein, C., Clark, J. D., Oh, U., Vasko, M. R., Wilcox, G. L., Overland, A. C., Vanderah, T. W., & Spencer, R. H. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.12.017 · Cited by 269
An Evidence-Based Systematic Review on the Management of Irritable Bowel Syndrome
Brandt, L. J., Chey, W. D., Foxx-Orenstein, A. E., Quigley, E. M. M., Schiller, L. R., Schoenfeld, P. S., Spiegel, B. M., Talley, N. J., & Moayyedi, P. (2009) · American Journal of Gastroenterology · doi:10.14309/00000434-200901001-00002 · Cited by 225
Metadata
- Authors
- MANGEL, A. W., BORNSTEIN, J. D., HAMM, L. R., BUDA, J., WANG, J., IRISH, W., & URSO, D.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2008-06-28
- Volume
- 28
- Issue
- 2
- Pages
- 239-249
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2092414646
- Cited by
- 136
- References
- 3
- FWCI
- 12.99
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. https://app.cochat.ai/papers/10.1111/j.1365-2036.2008.03730.x
- The paper
- MANGEL, A. W., BORNSTEIN, J. D., HAMM, L. R., BUDA, J., WANG, J., IRISH, W., & URSO, D. (2008). Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.2008.03730.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.